Bing

SEARCH HISTORY

Not everything goes according to plan the first time around. Sometimes it takes a stock a couple of tries or even more before a big rally finally gets going. So if the first breakout doesn't pan out, don't dismiss the stock just yet. Remember that trading ...
Investor's Business Daily · ByVincent Mao · 4/13/2015
Millennial generation investors who have been wading into the stock market the past few years probably think acing the stock market is a piece of cake. It’s hard to blame them. The bull market keeps pushing many of the stocks Millennials prefer higher ...
USA TODAY MONEY · ByMatt Krantz · 5/28/2015
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.Its primary areas of focus include primary areas of focus include human …
4 Traders · 1/7/2015
More from Bing News
BNN MARKET CALL Three top stock picks from Bank of Nova Scotia’s Jaime Carrasco BNN MARKET CALL Three top picks from CastleMoore’s Hap Sneddon BNN MARKET CALL Three top stock picks from Caldwell Investment’s Jennifer Radman
Globe and Mail · 5/4/2015
In its 1st quarter 2015 regulatory filing, Canyon Capital Advisors LLC reported that the value of its equity portfolio increased to $3.2 billion, from $2.4 billion at the end of 4th quarter 2014. The fund carried out a number of reforms in its equity ...
investcorrectly.com · 6/3/2015
Thanks to a big stock grant, Merck & Co.'s ($MRK) Kenneth Frazier vaulted to the highest echelons of pharma CEO pay last year. With a pay package valued at more than $25 million, Frazier beat out Pfizer's ($PFE) Ian Read and Johnson & Johnson's ($JNJ ...
FiercePharma · ByTracy Staton · 4/14/2015
If you are ready to step up and get the detailed options trades Gareth Soloway and Nick Santiago are taking live when they take them... enter the Options Alerts right here. Don't trade options? Then swing trade stocks with Gareth and Nick in the Research ...
In the Money Stocks · 6/19/2015
AbbVie shares sank more than 5 percent in pre-market trading on Thursday. The price tag AbbVie is paying is already turning heads. It’s almost double, for instance, the $11 billion Gilead Sciences (NASDAQ: GILD ... In 2014, Pharmacyclics said it paid ...
Xconomy · 3/5/2015
Relative long-term performance has been less of an issue for our Ultimate Stock-Pickers, with three fourths of the 22 fund managers on our Investment Manager Roster outperforming the S&P 500 index at the end of 2014 (as well as at the end of last week ...
news.morningstar.com · 2/18/2015
Biotechnology has been one of the best performing industries in the stock market over the past several years, yet we think the industry's drivers, including a robust pipeline, remain intact and have a positive fundamental outlook, asserts Todd Rosenbluth ...
The Money Show · 4/21/2015

Gilead Sciences

Company
Gilead Sciences is an American biotechnology company that discovers, develops and commercializes therapeutics. For many y…
Gilead Sciences is an American biotechnology company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B, hepatitis C, or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees. The company's name and logo refer to the Balm of Gilead.
Data from: Wikipedia